Dahlof B., Devereux R., Kjeldsen SE et al. Cardiovascular mortality and morbidity in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:995-1003.
2.
Lindholm LH, Ibsen H., Dahlöf B. et al. Cardiovascular mortality and morbidity in patients with diabetes in the LIFE study. Lancet2002;359:1004-10.
3.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703-13.
4.
Brady AJ, Oliver MA, Pittard JBSecondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ2001;322:1463.
5.
Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl J Med1993;329: 1456-62.
6.
Bilous RWAngiotensin II receptor blockade and type 2 diabetic nephropathy. Br J Diabetes Vasc Dis2002;2:101-05.
7.
SHEP Cooperative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA1991;265:3255-64.
8.
Staessen JA, Fagarda R., Thijsa L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757-64.
9.
Hansson L., Zanchetti A., Carruthers S. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment study. Lancet1998; 351:1755-62.
10.
Hansson L.The SCOPE trial. Oral Presentation, Hypertension Prague 2002, June 23rd-27th 2002. 19th Scientific Meeting of the International Society of Hypertension joint meeting with 12th European Meeting on Hypertension (European Society of Hypertension).
